NanoNewron

Executive Summary

NanoNewron is a private biotechnology company developing novel treatments for Alzheimer's disease and other neurodegenerative conditions. Its core innovation is the NewroBus™ platform, designed to overcome the blood-brain barrier (BBB) and enable delivery of large biologic drugs to the central nervous system. The lead candidate, NN-843, is a biologic TNF-α inhibitor aimed at reducing neuroinflammation in Alzheimer's patients. Founded in 2018 and based in San Diego, the company is at a preclinical to early clinical stage. The platform's ability to shuttle biologics across the BBB addresses a major bottleneck in CNS drug development, potentially unlocking new therapies for diseases with high unmet need. While no funding or partnership details are public, the focused pipeline and experienced team suggest a disciplined approach to advancing NN-843 toward the clinic. The company represents a high-risk, high-reward opportunity contingent on successful validation of its platform and candidate in human trials.

Upcoming Catalysts (preview)

• TBDIND filing for NN-84360% success
• TBDPreclinical proof-of-concept data for NewroBus platform in additional indications50% success
• TBDSeries A or B funding round announcement55% success